Immunovia AB (STO:IMMNOV), a manufacturer of healthcare devices, reported on Thursday that additional, more detailed data from the optimisation study of IMMray PanCan-d will be presented at PancreasFest 2019, to be held 24-26 July 2019 in Pittsburgh, US.
PancreasFest 2019 is a major annual meeting of pancreas physicians and translational researchers.
According to the company, the results demonstrated that the IMMray PanCan-d signature together with CA19-9 generated ROC AUC-values of 0.97, 0.98 and 0.96 when differentiating PDAC (pancreatic cancer) vs non-PDAC symptomatic individuals, healthy controls and type II diabetes, respectively. Similar results were achieved for all stages of PDAC.
These results show conclusively that IMMray PanCan-d has the capacity to differentiate between symptomatic, non-PDAC individuals, including type II diabetes, and all different stages of PDAC, Immunovia said.
This study collected and tested 937 patient samples from 150 PDAC (stage I-IV), 570 non-PDAC symptomatic individuals and 217 healthy individuals using IMMray PanCan-d in combination with CA19-9 ELISA assay.
To minimise confounding, pre-analytical variables, all patient samples were collected and processed using the same standard operating procedures, stored at -80°C and tested within a year after collection. Data analysis was performed using Immunovia software algorithms and accuracies, SVM ROC AUC-values, were determined for the different groups.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval